Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.7752W HIGH $1.84
Volume
45.57 K
Value Traded
104.21 K
Short % Float
0.74%
-1.92%Week
-19.18%1 Month
-12.45%3 Month
-19.69%6 Month
-100%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
16.23 M
EPS (TTM)
-0.78
P/E Ratio
-
Ent. Value
20.11 M
Total Shares
15.91 M
Float Shares
15.11 M
Insiders
5.01%
Institutions
8.05%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ALLR Catalyst Timeline
Dated clinical, regulatory and corporate events for Allarity Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Allarity Therapeutics, Inc.
352Total events
10Upcoming
73Tier-1 (high impact)
2020 to 2042Coverage
Upcoming catalysts 2
Event history 50
▲Platform ValidationPreclinical
Allarity expands in-house laboratory to include proteomics and cell line research
▲Patent GrantedstenoparibIP / Competition
Japan Patent Office granted patent covering stenoparib-specific DRP companion diagnostic
advanced ovarian cancersource ↗
●IpoCorporate
Allarity Acquisition Corp. publicly files Form S-1 Registration Statement with SEC for proposed IPO
▲Manufacturing MilestoneCMC / Inspection
CLIA Certificate of Registration obtained for in-house laboratory
◆Enrollment UpdatestenoparibTrial
Phase 2 trial of stenoparib in combination with temozolomide for relapsed SCLC currently enrolling
relapsed small cell lung cancer (SCLC)source ↗
▲Manufacturing MilestonestenoparibCMC / Inspection
Phase 3-ready API manufacturing campaign for stenoparib completed
▲Patent GrantedstenoparibIP / Competition
Expected formal grant of stenoparib DRP test patent
◆Timing GuidancestenoparibPresentation
Significant clinical data expected by late summer 2026
advanced, platinum-resistant or platinum-ineligible ovarian cancersource ↗
◆Topline ReadoutstenoparibClinical Data
Critical data expected by end of summer 2026 for pivotal registration trial
ovarian cancersource ↗
▲Patent GrantedstenoparibIP / Competition
Patent protection secured for stenoparib DRP in Europe and Australia into 2039
●Enrollment UpdatestenoparibTrial
Continued enrollment in SCLC combination trial with temozolomide
relapsed small cell lung cancersource ↗
▲Manufacturing MilestonestenoparibCMC / Inspection
CLIA certification obtained for in-house laboratory
▲Other Regulator MilestoneEx-US Regulatory
Obtained CLIA certification for in-house laboratory
●Poster PresentationstenoparibPresentation
Trial-in-Progress poster presentation at ESMO Gynaecological Cancers Congress 2026
advanced platinum-resistant or platinum-ineligible ovarian cancersource ↗
●Enrollment UpdatestenoparibTrial
Phase 2 trial of stenoparib in combination with temozolomide currently enrolling patients across multiple VA sites in the US
relapsed small cell lung cancersource ↗
▲Patent GrantedstenoparibIP / Competition
USPTO Notice of Allowance for stenoparib DRP companion diagnostic patent
◆Oral PresentationstenoparibPresentation
CEO presents at Precision Medicine Forum Europe 2026 on stenoparib dual inhibition and DRP biomarker
cancersource ↗
◆Enrollment UpdatestenoparibTrial
Phase 2 trial of stenoparib + temozolomide for relapsed SCLC currently enrolling patients
relapsed small cell lung cancersource ↗
▲Patent GrantedstenoparibIP / Competition
USPTO issued Notice of Allowance for stenoparib DRP companion diagnostic patent
▲Poster PresentationstenoparibPresentation
Poster: Stenoparib blocks WNT signaling and inhibits colorectal cancer cell lines
colorectal cancersource ↗
▲Poster PresentationstenoparibPresentation
Poster: DRP associated with enhanced overall survival in ovarian cancer patients treated with stenoparib
ovarian cancersource ↗
▲Oral PresentationstenoparibPresentation
AACR 2026 presentation of DRP findings in ovarian cancer
ovarian cancersource ↗
●Poster PresentationstenoparibPresentation
AACR 2026 preclinical data on stenoparib in colorectal cancer cell lines
colorectal cancersource ↗
▲Patent GrantedstenoparibIP / Competition
USPTO granted key U.S. patent covering stenoparib-specific DRP companion diagnostic
▼Equity OfferingCorporate
Closed $20 million non-convertible debt financing with Streeterville Capital
▲First Patient DosedstenoparibTrial
First patients dosed with stenoparib and temozolomide in VA-funded Phase 2 trial for relapsed SCLC
relapsed small cell lung cancersource ↗
▲Trial InitiationstenoparibTrial
Phase 2 trial of stenoparib + temozolomide in relapsed SCLC open for enrollment
recurrent small cell lung cancersource ↗
▲Oral PresentationstenoparibPresentation
AACR 2026 presentation of exploratory analysis of prior Phase 2 ovarian cancer cohort showing higher DRP scores associated with longer overall survival
advanced ovarian cancersource ↗
▲First Patient DosedstenoparibTrial
First patients dosed in VA-funded Phase 2 trial of stenoparib + temozolomide in relapsed SCLC
relapsed small cell lung cancersource ↗
▲Enrollment CompletestenoparibTrial
Continued enrollment in Phase 2 ovarian cancer trial under Fast Track
advanced ovarian cancersource ↗
▼Equity OfferingCorporate
Closed $20 million promissory note financing and secured $6 million equity line of credit
▲Enrollment UpdatestenoparibTrial
Phase 2 trial of stenoparib plus temozolomide in relapsed SCLC began enrolling at multiple U.S. VA sites
relapsed small cell lung cancer (SCLC)source ↗
◆Trial InitiationstenoparibTrial
VA-funded Phase 2 trial of stenoparib plus temozolomide expected to open for enrollment by year-end 2025
recurrent small cell lung cancersource ↗
●Oral PresentationPresentation
CEO presented at Biomarkers & Precision Medicine 2025 in London
▲Topline ReadoutstenoparibClinical Data
Median overall survival exceeds 25 months in ongoing Phase 2 trial
platinum-resistant or refractory ovarian cancersource ↗
◆Poster PresentationstenoparibPresentation
Poster presentation of updated Phase 2 clinical data for stenoparib at AACR Special Conference on Ovarian Cancer
advanced ovarian cancersource ↗
◆Oral PresentationPresentation
CEO Thomas Jensen to present at Biomarkers & Precision Medicine 2025 conference in London
▲Oral PresentationstenoparibPresentation
Updated Phase 2 ovarian cancer data presented at AACR Special Conference on Advances in Ovarian Cancer
advanced ovarian cancersource ↗
▲Full ResultsstenoparibClinical Data
Updated Phase 2 stenoparib data in advanced ovarian cancer presented at AACR Special Conference
advanced ovarian cancersource ↗
▲Fast Track DesignationstenoparibDesignation
FDA granted Fast Track designation for stenoparib in advanced ovarian cancer
advanced ovarian cancersource ↗
▲Fast Track DesignationstenoparibDesignation
FDA Fast Track designation for stenoparib in advanced ovarian cancer
advanced ovarian cancersource ↗
▲Partnership / LicenseCorporate
Allarity signs licensing and lab services agreement with EU biotech for DRP platform in breast cancer
breast cancersource ↗
▲Partnership / LicenseCorporate
Non-exclusive global license to selected breast cancer DRP algorithms and laboratory services agreement with EU biotech
Past FDA Catalysts and PDUFA Decisions
How ALLR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-12-31 | IXEMPRA (Ixabepilone) | Phase 2 interim results | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C40 / 100
Pipeline Score
$22M
Pipeline Value
Fair Value
Valuation Signal
4
Drugs Scored
1.4x
rNPV / MCap
Top 38%
Micro Cap(rank 251 of 658)
Percentile Rank
Allarity Therapeutics, Inc. carries a moderate pipeline score (40/100), with $1.6B risk-adjusted pipeline value, led by PARP inhibitor 2X-121 in Metastatic Breast Cancer (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PARP inhibitor 2X-121 Small moleculeCompletedNCT03562832 | Metastatic Breast Cancer | Phase 2 | COMPLETED | 20 | Aug 1, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every ALLR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| stenoparib Fast Track | advanced ovarian cancer | Phase 2 | 2026-09-30 | Higher pretreatment DRP scores were associated with longer overall survivalRead More | Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical DevelopmentRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Graff Jeremy R.Officer (See Remarks) | Grant/Award | 133,333 381,644 held | $0.00 | 01/28/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ALLR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ALLR for Q2 2026. | ||||
ALLR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ALLR ranks across every disease it competes in
Competitive Position is a premium feature
See how ALLR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialALLR News
ALLR▲ +8.8%on this news
Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development
Allarity Therapeutics has announced significant advancements in its Drug Response Predictor (DRP) technology, which is crucial for the clinical development of its drug stenoparib. The company has secured new patents and achieved CLIA certification for its in-house laboratory, enhancing its ability to select patients for treatment effectively. These developments aim to support Allarity's strategy for a pivotal trial and potential FDA approval.
Read more →ALLR▼ -6%on this news
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research
Allarity Therapeutics has expanded its laboratory capabilities to include proteomics and cell line research, enhancing its ability to conduct mechanism-of-action studies for its lead asset, stenoparib. This expansion is expected to improve research efficiency and broaden the range of services offered to external partners. The integration of these capabilities aims to deepen insights into cancer treatment and therapeutic targets.
Read more →ALLR▼ -5.1%on this news
Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development
Allarity Therapeutics has been granted a Japanese patent for its stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic, which is crucial for the drug's development in Japan. This patent extends protection until 2039 and supports Allarity's strategy to enhance its intellectual property portfolio. Stenoparib is currently in Phase 2 trials, showing potential benefits for patients with advanced ovarian cancer.
Read more →ALLRAllarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement
Allarity Therapeutics has announced the filing of a Registration Statement for its SPAC, Allarity Acquisition Corp., which aims for a $100 million IPO. The company continues to advance its clinical development of stenoparib, a dual PARP/Wnt pathway inhibitor, showing promising results in Phase 2 trials for advanced ovarian cancer. Jesper Hoiland will lead the SPAC as Chairman.
Read more →ALLRAllarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign
Allarity Therapeutics reported strong second quarter results, highlighting the completion of its stenoparib manufacturing campaign and the awarding of a key U.S. patent for its companion diagnostic. The company presented promising clinical data at AACR 2026, linking higher DRP scores to improved survival in advanced ovarian cancer. Additionally, Allarity secured CLIA certification for its laboratory, enhancing its capabilities for clinical trials.
Read more →ALLR▼ -5.8%on this news
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration
Allarity Therapeutics has achieved CLIA certification for its in-house laboratory, enabling it to conduct Drug Response Predictor (DRP) testing necessary for FDA registration of its lead agent, stenoparib. This certification allows Allarity to streamline operations, reduce turnaround times, and position itself as a key partner for European firms in U.S. clinical trials. The initiative supports the company's goal of advancing stenoparib for treating advanced ovarian cancer.
Read more →ALLRAllarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic
Allarity Therapeutics has received a key U.S. patent for its stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic, extending exclusivity until April 2042. This patent is crucial for the company's strategy to identify patients who will benefit most from stenoparib treatment, particularly in ovarian cancer. The patent also protects methods for predicting clinical benefits based on gene-expression profiles.
Read more →ALLR▲ +6.7%on this news
Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026
Allarity Therapeutics announced that it will present a Trial-in-Progress poster on its Phase 2 trial of stenoparib at the ESMO Gynaecological Cancers Congress 2026. The trial focuses on patients with advanced platinum-resistant or platinum-ineligible ovarian cancer. The presentation aims to showcase the study's design and clinical rationale, emphasizing the urgent need for new treatment options in this patient population.
Read more →ALLR▼ -10.6%on this news
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
Allarity Therapeutics reported its first-quarter results for 2026, highlighting progress in the development of stenoparib for various cancers. The company has received FDA Fast Track designation for stenoparib's use in advanced ovarian cancer and is expanding trials in relapsed small cell lung cancer. Financially, Allarity maintained a strong position with $29.8 million in cash and noted a reduced net loss per share compared to the prior year. Additionally, Allarity received a Notice of Allowance for a new companion diagnostic patent, potentially extending the drug's market exclusivity.
Read more →ALLRAllarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm
Allarity Therapeutics, a clinical-stage biopharma company, announced that its CEO, Thomas Jensen, will present at the Precision Medicine Forum Europe 2026 in Stockholm. Jensen will discuss the dual inhibition mechanism of stenoparib, a drug showing potential for treating multiple cancer types. The presentation will include insights on the Stenoparib DRP®, which is designed to identify patients likely to benefit from the treatment. This forum presents an opportunity for Allarity to highlight its clinical development efforts and engage in discussions about potential partnerships.
Read more →ALLRCopyright 2023 Allarity Therapeutics. All rights reserved. Nasdaq: ALLR Dual inhibition of PARP and WNT: A novel drug - biomarker combination in clinical trials Thomas Jensen, CEO 2 Allarity Therapeutics Legal Statement
Allarity Therapeutics has presented information on its proprietary gene expression technology and their drug stenoparib, which targets both PARP and the WNT pathway. Stenoparib has demonstrated a favorable profile for treating advanced ovarian cancer, showing durable clinical benefits. The company is currently enrolling patients in two new Phase 2 clinical trials while acknowledging various risks linked to funding and regulatory approvals. Forward-looking statements highlight potential uncertainties in the results of these clinical studies.
Read more →ALLR▲ +5.7%on this news· ran to +20% by day 3shared move
Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign
Allarity Therapeutics has reported that the Phase 3 manufacturing campaign for its drug stenoparib is progressing as planned, aiming for completion by the third quarter of 2026. This development is crucial for advancing stenoparib toward pivotal clinical trials for advanced ovarian cancer, especially with its recent FDA Fast Track designation. Moreover, Allarity has reported that all payments related to manufacturing have been fulfilled, alleviating concerns about future cash outlays. The company is optimistic about stenoparib's therapeutic potential based on encouraging survival data from previous studies.
Read more →ALLRAllarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office
Allarity Therapeutics announced that the USPTO has issued a Notice of Allowance for its stenoparib DRP® test patent. This patent, expected to be granted within three months, will provide exclusivity for stenoparib in conjunction with the DRP test until at least 2039. The patent aims to enhance the commercial potential of stenoparib by enabling better patient selection for treatment.
Read more →ALLR▲ +10.4%on this news
Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting
Allarity Therapeutics announced two posters at the AACR 2026 meeting showcasing data on stenoparib, a dual inhibitor, in colorectal and ovarian cancers. The posters highlight its mechanism of action and the positive association of the Drug Response Predictor (DRP) with overall survival in ovarian cancer patients. This data suggests a promising role for stenoparib in treating these significant cancer indications, emphasizing the importance of personalized treatment approaches. Both posters are now accessible on Allarity's website for further review.
Read more →ALLRAllarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
Allarity Therapeutics announced its financial results for the year ended December 31, 2025, reporting a cash position of $14.7 million and a reduction in total liabilities. The company highlighted significant clinical milestones, including the FDA's Fast Track designation for its drug stenoparib and the initiation of a new Phase 2 clinical trial protocol for ovarian cancer. Despite a year-over-year improvement in net loss by approximately $4.5 million, the company reported low annual revenue of $320,000.
Read more →ALLR▲ +21.6%on this news
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization
Allarity Therapeutics has successfully closed a $20 million financing round aimed at advancing its drug, stenoparib, towards FDA approval and eventual commercialization. This financing is structured as non-convertible debt and is expected to extend the company's cash runway into mid-2028. The funds will primarily support the completion of a Phase 2 clinical trial for advanced ovarian cancer and facilitate preparations for a pivotal trial. CEO Thomas Jensen emphasized the financing's role in enhancing both clinical development and the company's strategic initiatives.
Read more →ALLR▲ +8.7%on this news· ran to +27% by day 1
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need
Allarity Therapeutics has initiated dosing of the first patients in a Phase 2 trial for stenoparib combined with temozolomide, targeting relapsed small cell lung cancer (SCLC). Funded by the U.S. Department of Veterans Affairs, the trial aims to address significant unmet medical needs in this patient population. Stenoparib's dual action may enhance treatment efficacy while minimizing toxicity, offering hope for better outcomes in SCLC.
Read more →ALLR▼ -8.1%on this news
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment
Allarity Therapeutics has opened enrollment for a Phase 2 clinical trial evaluating stenoparib in combination with temozolomide for relapsed small cell lung cancer. Conducted in collaboration with the U.S. Department of Veterans Affairs, the trial aims to assess safety and efficacy while utilizing a blood-based biomarker for patient selection. Stenoparib's favorable safety profile and unique mechanism may provide new treatment options for patients with limited alternatives.
Read more →ALLR▲ +6.9%on this news
Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders
Allarity Therapeutics' CEO letter highlights the company's progress in 2025, focusing on the development of stenoparib, a dual PARP and WNT pathway inhibitor. The company has achieved FDA Fast Track Designation for stenoparib and is expanding its clinical applications to other cancers, including recurrent Small Cell Lung Cancer. Financially, Allarity has strengthened its position while maintaining a disciplined operating model. Looking ahead to 2026, the company aims to deepen its focus on stenoparib's approval and explore additional therapeutic opportunities.
Read more →About Allarity Therapeutics, Inc.
Headquarters24 SCHOOL ST., 2ND FLOOR, BOSTON, MA, 02108
Founded2004
BIOPHARMAWATCH ELITE PLUS
Trade the next ALLR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime